newsfilter
← Latest News
PR Newswire·

Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent

Lipella awarded $1.35m grant in 2022 for development of intravesical contrast-enhanced magnetic resonance imaging (ICE-MRI) technology. PITTSBURGH, April 5, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO)